Specifically, patients with NASH and fibrosis have lower hepatic carbamoyl-phosphate synthase 1 (CPS1) and ornithine transcarbamylase (OTC) mRNA levels and reduced CPS1 protein levels than healthy controls leading to increased circulating ammonia (16). The gene discussed is CPS1; the disease is metabolic dysfunction-associated steatohepatitis.